cardiac
intensivist
must
adept
identifi
stabil
treat
ahf
patient
depend
practic
environ
patient
popul
profici
begin
identifi
ahf
patient
box
determin
patient
ahf
potenti
heart
transplant
candid
manag
critic
ill
heart
transplant
candid
includ
intensif
intraven
diuret
vasodil
inotrop
interpret
hemodynam
guid
therapi
heart
failur
hf
continu
lead
caus
morbid
mortal
unit
state
approxim
million
american
current
live
hf
number
expect
increas
million
new
case
hf
diagnos
year
mortal
remain
approxim
gross
annual
cost
manag
hf
approxim
billion
expect
reach
billion
strategi
avert
cost
focu
prevent
consid
new
hf
case
preced
histori
hypertens
technolog
advanc
continu
improv
therapeut
option
outcom
patient
live
advanc
hf
ahf
ultim
heart
transplant
provid
best
longterm
outcom
ahf
patient
identif
optim
time
mechan
circulatori
support
mc
profici
immedi
postop
care
follow
heart
transplant
compet
manag
longerterm
posttranspl
complic
requir
cardiac
intens
care
unit
cicu
support
primari
graft
dysfunct
acut
chronic
reject
manag
denerv
heart
cardiac
allograft
vasculopathi
complic
immunosuppress
almost
million
american
live
hf
approxim
patient
ahf
american
colleg
cardiolog
american
heart
associ
accaha
stage
heart
failur
ahf
stage
patient
identifi
determin
high
risk
rehospit
heart
transplant
mechan
circulatori
support
candidaci
determin
critic
optim
patient
outcom
time
select
right
intervent
right
patient
limit
suppli
donor
heart
warrant
strict
select
criteria
ensur
list
heart
transplant
like
benefit
box
outlin
common
element
use
evalu
potenti
cardiac
transplant
candid
box
outlin
common
indic
heart
transplant
import
solid
background
indic
ensur
necessari
treatment
delay
unnecessari
test
treatment
perform
addit
intensivist
must
recogn
sever
hf
suboptim
treat
hf
insuffici
indic
heart
transplant
mani
patient
consid
advanc
therapi
may
still
stage
c
hf
requir
medic
optim
furthermor
hf
team
must
understand
heart
transplant
option
unlik
success
patient
absolut
rel
contraind
exist
box
practic
vari
among
transplant
center
recogn
risk
factor
comorbid
help
determin
safeti
appropri
transplant
ahf
patient
critic
optim
posttranspl
outcom
member
everi
transplant
center
must
work
individu
polici
determin
accept
amount
risk
maintain
optim
outcom
age
greater
year
consid
rel
contraind
heart
transplant
base
work
mancini
lietz
limit
data
septuagenarian
goldstein
et
al
review
patient
older
year
underw
heart
advanc
nyha
function
class
nyha
class
iiiiv
b
episod
hf
decompens
character
either
volum
overload
reduc
cardiac
output
c
object
evid
sever
cardiac
dysfunct
shown
one
follow
lvef
ii
pseudonorm
restrict
mitral
inflow
pattern
iii
pcwp
mm
hg
andor
rap
mm
hg
iv
elev
bnp
ntprobnp
plasma
level
absenc
noncardiac
caus
sever
impair
function
capac
shown
one
follow
inabl
exercis
ii
distanc
walk
minut
iii
peak
oxygen
consumpt
vo
e
histori
hf
hospit
past
month
f
presenc
previou
featur
despit
attempt
optim
therapi
unless
poorli
toler
contraind
cardiac
resynchron
therapi
indic
clinic
event
suggest
ahf
frequent
hf
hospit
ed
visit
past
month
b
progress
declin
renal
function
c
cardiac
cachexia
intoler
ace
inhibitor
hypotens
worsen
renal
function
e
intoler
hypotens
worsen
hf
f
frequent
systol
blood
pressur
mm
hg
g
persist
dyspnea
dress
bath
requir
rest
h
inabl
walk
block
level
ground
dyspnea
fatigu
escal
diuret
maintain
euvolemia
furosemid
dose
mg
day
use
metolazon
j
progress
declin
serum
sodium
level
meql
k
frequent
icd
shock
transplant
demonstr
median
unadjust
surviv
year
compar
year
sexagenarian
conclud
select
heart
transplant
candid
age
year
still
deriv
great
benefit
cardiac
transplant
gener
accept
heart
transplant
program
develop
specif
donor
recipi
criteria
context
local
organ
avail
qualiti
ensur
optim
outcom
high
probabl
transplant
patient
list
continu
wors
outcom
patient
extrem
bodi
mass
index
bmi
spectrum
bmi
less
kgm
greater
kgm
class
iia
recommend
patient
achiev
bmi
less
kgm
list
heart
transplant
addit
grow
bodi
literatur
demonstr
safeti
improv
longterm
outcom
morbidli
obes
ahf
patient
undergo
bariatr
surgeri
abl
go
onto
heart
transplant
patient
diabet
mellitu
dm
minim
endorgan
damag
excel
shortand
intermediateterm
outcom
heart
transplant
steroid
caus
postprandi
hyperglycemia
lead
worsen
blood
glucos
control
tacrolimu
cyclosporin
like
lead
endorgan
damag
commonli
nephrotox
andor
neurotox
guidelin
adopt
class
iia
recommend
state
rel
contraind
heart
transplant
patient
dm
endorgan
damag
persist
level
greater
ahf
often
lead
worsen
renal
hepat
function
cardioren
syndrom
hepat
congest
rapidli
progress
irrevers
stage
singl
test
optim
predictor
recoveri
follow
heart
transplant
current
guidelin
recommend
assess
renal
function
use
estim
glomerular
filtrat
rate
egfr
creatinin
clearanc
evalu
often
includ
proteinuria
assess
renal
ultrasonographi
consult
nephrologist
liver
challeng
kidney
predict
degre
irrevers
damag
screen
tool
assess
hepat
synthet
function
eg
intern
normal
ratio
inr
platelet
albumin
often
mislead
imag
liver
includ
abdomin
ultrasound
abdomin
comput
tomographi
ct
often
yield
inconsist
result
liver
biopsi
debat
gold
standard
optim
liver
biopsi
specimen
still
rate
discord
fibrosi
stage
inher
risk
sampl
bia
newer
imag
techniquessuch
ultrasound
elastographyfibroscan
perfus
imag
ct
magnet
reson
elastographi
mre
may
improv
diseas
assess
transplant
candid
margin
hepat
renal
function
risk
periop
period
higher
longterm
morbid
mortal
administr
intraven
nitroprussid
inotrop
agent
safe
assum
abnorm
secondari
mark
degre
cardiac
dysfunct
mani
ahf
center
use
indwel
pa
cathet
allow
inpati
hemodynam
optim
select
patient
sever
cardiac
dysfunct
may
requir
temporari
mc
tmc
fulli
unload
lv
allow
optim
hemodynam
strategi
may
improv
patient
select
durabl
mc
ultim
patient
outcom
durabl
mc
success
lower
lv
fill
pressur
month
lead
neg
remodel
strategi
may
provid
margin
candid
opportun
becom
accept
heart
transplant
rhc
routin
perform
patient
base
risk
factor
clinic
sever
diseas
consid
heart
transplant
episod
decompens
patient
found
unaccept
high
pa
pressur
admiss
cicu
pa
cathet
placement
medic
optim
help
prior
transplant
young
donor
heart
right
ventricl
rv
limit
exposur
elev
pulmonari
pressur
high
risk
acut
rv
failur
transplant
individu
pulmonari
hypertens
patient
irrevers
pulmonari
hypertens
may
consid
combin
heartlung
transplant
sever
symptomat
cerebrovascular
peripher
vascular
diseas
significantli
hinder
recoveri
cardiac
rehabilit
follow
heart
transplant
registri
data
transplant
patient
histori
symptomat
cerebrovascular
diseas
sever
chronic
lung
diseas
increas
risk
complic
periop
period
independ
decreas
patient
function
capac
chanc
surviv
follow
transplant
patient
pulmonari
dysfunct
immunosuppress
therapi
demonstr
increas
incid
pulmonari
infect
data
limit
singlecent
review
heart
transplant
patient
demonstr
patient
fev
forc
expiratori
volum
one
second
fvc
forc
vital
capac
ratio
less
signific
prolong
intub
signific
reduct
surviv
compar
patient
fev
fvc
ratio
greater
similar
outcom
seen
patient
diffus
capac
lung
carbon
monoxid
dlco
less
caution
exercis
evalu
patient
abnorm
pulmonari
function
test
heart
transplant
left
ventricular
lv
dysfunct
common
caus
pulmonari
hypertens
worldwid
pulmonari
hypertens
increas
risk
right
ventricular
failur
periop
period
significantli
worsen
mortal
patient
consider
heart
transplant
undergo
right
heart
catheter
rhc
sever
key
paramet
determin
time
rhc
includ
pulmonari
vascular
resist
pvr
transpulmonari
gradient
tpg
diastol
pulmonari
gradient
pulmonari
arteri
pa
systol
pressur
greater
mm
hg
tpg
greater
mm
hg
pvr
greater
wood
unit
class
recommend
perform
vasodil
challeng
paramet
correct
initi
hemodynam
measur
eg
system
ill
life
expect
year
despit
ht
includ
activ
recent
solid
organ
blood
malign
within
year
eg
leukemia
lowgrad
neoplasm
prostat
persist
elev
prostatespecif
antigen
aid
frequent
opportunist
infect
system
lupu
erythematosu
sarcoid
amyloidosi
multisystem
involv
still
activ
amen
treatment
irrevers
renal
hepat
dysfunct
patient
consid
ht
signific
obstruct
pulmonari
diseas
fev
lmin
may
suitabl
ht
inotrop
support
hemodynam
manag
produc
creatinin
mgdl
creatinin
clearanc
ml
min
transplant
may
also
advis
combin
heartkidney
transplant
independ
predictor
increas
allcaus
mortal
patient
ahf
refer
heart
transplant
difficulti
evalu
frailti
lack
standard
flint
et
al
rais
concern
frailti
consid
suggest
frail
patient
may
appropri
treat
advanc
therapi
other
may
therefor
current
definit
need
addit
refin
studi
comprehens
team
evalu
aspect
transplant
candidaci
includ
psychosoci
factor
critic
optim
patient
outcom
appropri
patient
select
robust
social
support
system
essenti
success
patient
undergo
heart
transplant
vital
natur
medic
adher
consist
followup
earli
recognit
abnorm
sign
symptom
paramount
qualiti
life
longterm
surviv
intern
societi
heart
lung
transplant
ishlt
guidelin
provid
class
iia
recommend
patient
social
support
deem
insuffici
achiev
compliant
care
outpati
set
may
regard
rel
contraind
transplant
everi
heart
transplant
candid
receiv
care
thorough
evalu
qualifi
profession
psychiatr
condit
includ
activ
substanc
abus
prior
substanc
abus
without
clearli
document
abstin
may
profoundli
increas
risk
posttranspl
complic
tobacco
use
alcohol
abus
categor
illicit
drug
estim
scope
substanc
abus
marijuana
gain
increas
attent
individu
state
pass
law
legal
use
psycholog
stress
heart
transplant
longterm
sequela
demand
patient
invest
commit
therefor
import
psychosoci
issu
address
prior
heart
transplant
financi
burden
heart
transplant
vari
significantli
region
insur
coverag
estim
averag
bill
charg
associ
heart
transplant
unit
state
figur
includ
nonmed
cost
associ
food
lodg
transport
transplant
center
need
child
care
lost
wage
patient
famili
member
may
requir
leav
work
function
primari
caretak
insur
cover
expens
incur
transplant
procedur
coverag
vari
dramat
medic
longterm
care
comprehens
transplant
team
dedic
financi
specialist
assess
cost
futur
care
base
individu
insur
coverag
goal
financi
team
ensur
document
increas
risk
stroke
function
declin
follow
transplant
part
routin
pretranspl
evalu
carotid
doppler
ultrasound
perform
patient
coronari
arteri
diseas
patient
older
year
signific
carotid
occlus
diseas
identifi
surgic
correct
strongli
consid
transplant
histori
andor
clinic
sign
symptom
peripher
vascular
diseas
pvd
warrant
appropri
screen
assess
may
includ
lower
extrem
arteri
doppler
evalu
assess
anklebrachi
index
transplant
individu
activ
infect
extrem
high
risk
critic
import
immunosuppress
immedi
postop
leav
littl
room
error
routin
consult
infecti
diseas
specialist
prior
transplant
activ
infecti
concern
inpati
transplant
candid
particularli
risk
develop
nosocomi
infect
meticul
attent
ongo
indic
indwel
line
foley
cathet
help
avoid
prevent
infect
practic
consist
steril
precaut
perform
line
mainten
help
prevent
catheterrel
infect
use
low
threshold
first
sign
fever
leukocytosi
initi
thorough
investig
recommend
time
necessari
defer
patient
candidaci
downgrad
patient
list
statu
extens
infecti
workup
perform
potenti
transplant
candid
final
thorough
dental
examin
conduct
list
identifi
patient
poor
dentit
subclin
sourc
infect
also
import
recogn
patient
test
posit
cytomegaloviru
toxoplasma
gondii
epsteinbarr
viru
hepat
human
immunodefici
viru
hiv
prior
tuberculosi
tb
infect
still
consid
heart
transplant
transplant
infecti
diseas
physician
instrument
guid
therapi
patient
popul
especi
initi
immunosuppress
transplant
significantli
increas
incid
malign
larg
relat
effect
chronic
immunosuppress
prognosi
rate
progress
type
malign
respons
treatment
likelihood
widespread
metastas
must
thoroughli
discuss
consid
prior
proceed
heart
transplant
ongo
studi
need
guid
decis
process
especi
individu
chemotherapyinduc
cardiomyopathi
increasingli
older
popul
undergo
heart
transplant
accur
assess
frailti
grow
area
interest
frailti
clinic
recogn
syndrom
decreas
physiolog
reserv
often
unmask
minor
stressor
defin
posit
respons
three
follow
five
compon
weak
grip
strength
slow
walk
speed
poor
appetit
physic
inact
exhaust
frailti
mortal
rate
remain
unaccept
high
updat
heart
alloc
polici
sixtier
system
accept
implement
wait
heart
transplant
becom
longer
candid
due
sever
factor
surg
number
candid
increas
surviv
use
mc
bridg
transplant
plateau
accept
donor
heart
alloc
scarc
resourc
warrant
invest
research
technolog
help
expand
donor
pool
effort
deliv
best
outcom
highest
qualiti
life
patient
intensivist
must
recogn
role
famili
prepar
capabl
deal
financi
burden
heart
transplant
undergo
heart
transplant
physic
emot
psycholog
challeng
burdensom
financi
strain
add
complex
ultim
lead
nonadher
treatment
plan
protocol
result
poor
outcom
heart
transplant
remain
effect
treatment
select
patient
ahf
transplant
surviv
significantli
improv
shown
fig
surviv
year
nearli
respect
dramat
improv
ahf
patient
live
new
york
heart
associ
nyha
class
iv
stage
heart
failur
whose
surviv
approach
zero
heart
transplant
limit
primarili
worsen
supplydemand
mismatch
recent
nearli
heart
transplant
perform
nationwid
yet
patient
wait
list
surviv
patient
ahf
await
heart
transplant
face
challeng
diseas
process
limit
donor
avail
region
differ
wait
time
fig
tabl
increasingli
complex
donor
alloc
system
sinc
annual
number
cardiac
transplant
perform
unit
state
slowli
increas
approxim
per
year
median
wait
time
patient
list
statu
region
approxim
day
criteria
requir
patient
becom
list
statu
present
tabl
nearli
decad
sinc
last
revis
heart
alloc
polici
unit
state
although
time
advanc
medic
therapi
drastic
improv
mc
option
help
prolong
surviv
statu
htx
heart
transplant
list
statu
frequent
outpati
visit
assess
adequ
metabol
cellular
nutrit
health
critic
prevent
irrevers
endorgan
damag
common
symptom
physic
sign
object
measur
cardiopulmonari
statu
list
box
singl
paramet
identifi
individu
would
benefit
heart
transplant
lv
eject
fraction
lvef
previous
thought
primari
indic
worsen
prognosi
surviv
know
lvef
fail
consist
predict
outcom
alon
inadequ
indic
heart
transplant
nearli
hf
patient
hf
preserv
eject
fraction
hfpef
field
ahf
must
find
better
way
predict
outcom
obtain
object
data
point
assist
predict
outcom
patient
popul
two
diagnost
test
rhc
cardiopulmonari
exercis
test
cpet
provid
reliabl
object
data
help
evalu
patient
ahf
rhc
class
recommend
adult
candid
prepar
list
heart
transplant
addit
rhc
period
perform
candid
await
heart
transplant
frequenc
person
individu
situat
develop
ambulatori
pa
pressur
monitor
system
cardiomem
abbott
devic
futur
guidelin
may
need
consid
altern
recurr
invas
procedur
multidisciplinari
cardiovascular
care
team
fig
includ
cardiothorac
surgeon
mechan
circulatori
support
team
interventionalstructur
cardiologist
critic
care
team
ahf
cardiologist
supportivepalli
care
physician
collabor
approach
fundament
optim
patient
care
sever
random
control
trial
demonstr
multidisciplinari
teambas
care
patient
ahf
reduc
mortal
hf
hospit
allcaus
hospit
addit
studi
confirm
implement
teambas
care
ahf
decreas
length
stay
improv
qualiti
life
pretranspl
patient
manag
start
earli
recognit
patient
ahf
sever
level
care
patient
ahf
await
heart
transplant
may
requir
physician
must
determin
suffici
mani
patient
manag
outpati
set
remain
use
hf
prognosi
score
heart
failur
surviv
score
hfss
seattl
heart
failur
model
shfm
may
use
predict
morbid
mortal
ambulatori
ahf
patient
assist
discrimin
patient
list
transplant
predict
patient
surviv
less
recent
trial
built
upon
foundat
work
mancini
colleagu
use
cpet
tool
predict
outcom
ahf
patient
found
peak
vo
less
mlkg
per
minut
use
predict
mortal
benefit
heart
transplant
patient
ahf
cpet
integr
recent
scientif
statement
multipl
studi
demonstr
util
measur
exercis
capac
oxygen
consumpt
assist
determin
degre
cardiac
dysfunct
prognosi
goal
may
necessit
dose
adjust
howev
everi
effort
made
continu
therapi
deescal
gdmt
disservic
hf
patient
term
mortal
clinic
indic
occas
renal
dysfunct
symptomat
hypotens
electrolyt
disturb
frequent
reason
discontinu
angiotensinconvert
enzym
ace
inhibitor
angiotensin
ii
receptor
blocker
arb
sacubutrilvalsartan
angiotensin
receptor
neprilysin
inhibitor
arni
aldosteron
antagonist
patient
longer
toler
gdmt
recogn
individu
need
advanc
therapi
patient
renal
dysfunct
warrant
special
attent
frequent
laboratori
assess
initi
adjust
dosag
medic
gener
systol
blood
pressur
less
mmhg
serum
creatinin
greater
mgdl
men
greater
mgdl
women
serum
potassium
level
greater
mmoll
give
paus
clinician
consid
initi
ace
inhibitor
arb
arni
aldosteron
antagonist
although
patient
serum
sodium
less
mml
increas
risk
symptomat
hypotens
ace
inhibitor
deriv
greatest
benefit
hydralazin
isosorbid
dinitr
uniqu
class
recommend
use
african
american
nyha
class
iii
iv
hf
reduc
eject
fraction
hfref
still
class
iia
recommend
symptomat
patient
hfref
take
ace
inhibitor
arb
arni
digoxin
remain
controversi
drug
class
iia
recommend
patient
hfref
reduc
hospit
hf
guidelin
recommend
mg
daili
even
lower
dose
patient
greater
year
old
impair
renal
function
low
lean
bodi
mass
serum
level
ngml
suggest
higher
drug
level
unlik
provid
addit
benefit
like
lead
toxic
especi
level
greater
ngml
increas
risk
digoxin
toxic
occur
concomit
amiodaron
use
close
monitor
done
patient
labil
renal
function
addit
calcium
channel
blocker
recommend
patient
hfref
avoid
except
amlodipin
treatment
hypertens
angina
last
anticoagul
recommend
patient
chronic
hfref
without
atrial
fibril
prior
thromboembol
event
embol
event
presum
cardiac
sourc
natur
diseas
cours
ahf
lead
progress
function
declin
mani
clinic
sign
symptom
list
box
one
mani
challeng
treat
ahf
patient
understand
success
strategi
treat
one
patient
alway
translat
success
strategi
next
patient
previous
mention
low
threshold
hospit
intensif
therapi
avoid
endorgan
damag
import
slow
diseas
progress
ahf
progress
therapi
often
escal
intraven
diuret
intraven
inotrop
agent
technolog
year
shfm
mediumto
highrisk
rang
hfss
consid
reason
threshold
list
cardiac
transplant
risk
calcul
shfm
develop
predict
event
outpati
cohort
limit
applic
hospit
ahf
patient
surviv
score
help
prognost
list
patient
heart
transplant
base
surviv
risk
score
class
iii
recommend
avoid
hf
progress
toward
advanc
stage
patient
becom
increasingli
suscept
decompens
event
may
well
toler
earli
diseas
process
becom
increasingli
difficult
patient
manag
without
inpati
care
box
list
acut
precipit
acut
decompens
hf
also
discuss
greater
detail
chapter
mani
precipit
condit
easili
revers
lead
clinician
quickli
review
optim
guidelinedirect
medic
therapi
gdmt
indic
implant
cardiovert
defibril
icd
cardiac
resynchron
therapi
crt
ensur
revers
structur
abnorm
contribut
patient
condit
strategi
use
earlier
cours
diseas
recent
review
consecut
patient
list
heart
transplant
patient
icd
place
time
list
patient
suffer
decompens
due
arrhythmia
may
benefit
electrophysiolog
evalu
option
includ
abl
procedur
optim
antidysrhythm
regimen
case
surgic
sympathectomi
treat
potenti
lethal
ventricular
arrhythmia
loss
sinu
rhythm
thought
precipit
decompens
robust
attempt
made
establish
maintain
sinu
rhythm
base
accaha
guidelin
amiodaron
dofetilid
prefer
antidysrhythm
drug
larg
base
neutral
effect
mortal
hf
popul
rel
common
patient
present
hospit
decompens
hf
withheld
cardiogen
shock
tissu
hypoperfus
andor
initi
inotrop
therapi
withheld
patient
take
develop
decompens
hf
maintain
medic
possibl
hemodynam
dietari
indiscret
high
salt
intak
pulmonari
infect
medic
chang
nonadher
arrhythmia
antidysrhythm
medic
anemia
thyroid
dysfunct
box
acut
precipit
acut
decompens
heart
failur
avoidhf
trial
may
help
determin
earli
use
uf
reduc
heart
failur
event
role
pretranspl
patient
care
pleural
effus
ascit
common
sign
congest
patient
experi
signific
relief
follow
thoracentesi
paracentesi
imper
understand
restor
normal
volum
statu
markedli
enhanc
respons
vasodil
decongest
patient
may
afford
opportun
reiniti
gdmt
previous
ineffect
dose
may
result
effect
even
excess
vasodil
although
common
initi
gdmt
lead
rise
creatinin
diuret
withheld
mani
effect
treat
patient
experi
increas
creatinin
blood
urea
nitrogen
often
much
accept
one
strategi
deal
worsen
renal
function
slow
rate
diuresi
patient
longer
volum
overload
avoid
excess
vasodil
patient
lowoutput
state
cardiac
output
must
optim
effect
diuresi
achiev
without
compromis
endorgan
function
ahf
patient
await
heart
transplant
requir
inotrop
support
success
bridg
mc
heart
transplant
guid
princip
use
inotrop
appli
low
dose
possibl
shortest
necessari
durat
achiev
clinic
goal
patient
requir
placement
longterm
iv
access
initi
home
inotrop
infus
cardiac
intensivist
comfort
use
dobutamin
milrinon
inotrop
support
patient
hypotens
dopamineand
occasion
epinephrinecan
provid
blood
pressur
inotrop
support
data
de
backer
et
al
compar
dopamin
levoph
patient
present
shock
note
signific
differ
mortal
howev
patient
dopamin
compar
patient
levoph
experienc
arrhythmia
p
furthermor
subgroup
analysi
found
cardiogen
shock
patient
mortal
significantli
higher
treat
dopamin
compar
treat
levoph
p
situat
isoproterenol
may
also
consid
veryshortterm
support
understand
physiolog
sideeffect
profil
medic
allow
precis
therapi
ahf
patient
gener
advers
effect
medic
durat
depend
dose
depend
combin
agent
lower
dose
may
help
avoid
advers
event
patient
depend
upon
continu
iv
inotrop
support
poor
prognost
indic
signal
final
stage
ahf
unit
network
organ
share
uno
statu
list
acknowledg
increas
morbid
mortal
associ
continu
iv
inotrop
thu
patient
given
higher
prioriti
wait
list
caution
must
exert
transit
inotrop
support
patient
frequent
becom
overli
sensit
afterload
reduct
set
intravascular
deplet
titrat
inotrop
support
therefor
special
attent
given
assess
patient
volum
statu
toler
vasodil
advanc
made
role
tmc
increasingli
import
common
patient
fail
intraven
inotrop
agent
undergo
placement
intraaort
balloon
pump
iabp
tmc
tempor
measur
determin
patient
success
bridg
longterm
solut
heart
transplant
durabl
mc
advanc
stage
hf
frequent
character
deescal
therapi
initi
well
toler
sever
common
clinic
problem
aris
stage
discuss
greater
detail
mani
patient
present
acut
decompens
hf
critic
condit
requir
admiss
cicu
recogn
level
requir
care
gain
control
stabil
progress
diseas
critic
skill
set
determin
life
death
patient
popul
inappropri
triag
patient
risk
suffer
compromis
endorgan
function
ultim
worsen
posttranspl
morbid
mortal
data
evalu
studi
congest
heart
failur
pulmonari
arteri
catheter
effect
escap
trial
play
signific
role
decreas
use
invas
hemodynam
monitor
pa
cathet
guidelin
provid
class
iii
recommend
routin
use
invas
hemodynam
monitor
normotens
patient
acut
decompens
hf
howev
invas
hemodynam
monitor
guid
therapi
patient
respiratori
distress
clinic
evid
impair
perfus
still
class
recommend
role
invas
hemodynam
monitor
ahf
patient
critic
step
determin
revers
elev
pulmonari
pressur
increas
pulmonari
vascular
resist
pa
cathet
therapeut
data
provid
help
guid
therapi
prognosi
possibl
improv
outcom
heart
transplant
symptomat
relief
patient
ahf
often
achiev
use
loop
diuret
high
dose
continu
infus
strategi
prove
compar
diuret
optim
strategi
evalu
dose
trial
albeit
low
infus
dose
ahf
progress
diuret
resist
develop
effect
diuresi
often
necessit
combin
loop
diuret
metolazon
intraven
thiazid
creatinin
rise
diuret
resist
develop
intensivist
must
recogn
worsen
cardioren
syndrom
cardioren
syndrom
may
requir
support
inotrop
infus
use
tmc
help
reliev
congest
improv
renal
function
refractori
case
administr
nesiritid
success
promot
diuresi
nesiritid
gain
popular
follow
vasodil
manag
acut
chf
vmac
trial
subsequ
lost
favor
acut
studi
clinic
effect
nesiritid
decompens
heart
failur
trial
ascendhf
trial
publish
find
ultrafiltr
uf
studi
ultrafiltr
versu
iv
diuret
patient
hospit
acut
decompens
chf
unload
trial
cardioren
rescu
studi
acut
decompens
heart
failur
carresshf
trial
mix
result
ongo
enrol
aquapheresi
versu
intraven
diuret
hospit
heart
failur
await
transplant
home
field
heart
transplant
recogn
need
decreas
time
wait
list
relat
mortal
new
system
six
tier
propos
undergon
public
comment
expert
refin
optn
uno
approv
revis
adult
alloc
system
ongo
modif
new
system
better
incorpor
advanc
mc
increas
role
help
success
bridg
candid
heart
transplant
organ
donor
transplant
recipi
pair
base
abo
blood
type
match
categori
abo
match
abo
ident
abo
compat
abo
incompat
abo
blood
type
play
import
role
expect
wait
time
statu
patient
consid
list
critic
ill
patient
may
need
mc
success
bridg
transplant
current
guidelin
ishlt
provid
class
recommend
adult
heart
donor
bodi
weight
within
recipi
recommend
femaletomal
donat
within
guidelin
state
male
donor
averag
weight
kg
safe
use
recipi
regardless
weight
drive
forc
morbid
mortal
heart
transplant
highli
relat
time
transplant
understand
tempor
relationship
may
help
guid
initi
workup
treatment
heart
transplant
patient
present
nonspecif
symptom
especi
cicu
fig
cardiac
intensivist
take
care
heart
transplant
patient
import
recogn
infect
reject
episod
treatabl
furthermor
advanc
durabl
tmc
expand
rescu
option
candid
pool
physiolog
transplant
heart
far
differ
cardiac
patient
immedi
postop
period
transplant
heart
usual
requir
higherthannorm
fill
pressur
pa
cathet
play
critic
role
target
optim
fill
pressur
everi
posttranspl
patient
gener
optim
rightsid
preload
usual
right
atrial
pressur
mm
hg
optim
leftsid
preload
pulmonari
capillari
wedg
mm
hg
elev
fill
pressur
thought
driven
dramat
decreas
ventricular
complianc
diastol
dysfunct
transplant
given
degre
diastol
dysfunct
limit
stroke
volum
follow
heart
transplant
heart
rate
beatsmin
target
maintain
optim
cardiac
output
role
pa
catheterguid
manag
hemodynam
special
attent
svr
help
avoid
clinic
scenario
renal
vascular
vasodil
renal
vascular
congest
lead
rise
serum
creatinin
anticip
differenti
event
help
prevent
patient
mismanag
start
low
go
slow
appropri
strategi
come
oral
vasodil
dose
prior
discontinu
inotrop
therapi
clinic
scenario
inotrop
wean
unsuccess
plan
palli
care
bridg
mc
bridg
transplant
put
place
patient
discharg
inotrop
support
palli
icd
placement
consid
given
increas
risk
arrhythmiarel
sudden
cardiac
death
ahf
patient
requir
inotrop
support
pa
cathet
placement
may
provid
hemodynam
data
suggest
significantli
elev
svr
situat
use
intraven
vasodil
nitroprussid
nitroglycerin
offer
import
clinic
benefit
patient
ischem
cardiomyopathi
pulmonari
hypertens
complic
sever
right
heart
failur
may
respond
well
intraven
nitroglycerin
nitroprussid
also
use
set
caution
must
exercis
patient
renal
failur
higher
risk
develop
thiocyan
toxic
mc
continu
play
increas
role
treatment
ahf
past
year
patient
implant
unit
state
current
rate
implant
exce
patient
per
year
approxim
recipi
list
heart
transplant
time
implant
addit
implant
plan
bridgetotranspl
btt
strategi
technolog
advanc
rapidli
field
surviv
approach
still
well
surviv
year
heart
transplant
durabl
temporari
devic
includ
extracorpor
membran
oxygen
ecmo
like
play
increas
role
improv
surviv
heart
transplant
mc
discuss
much
greater
detail
chapter
includ
percutan
surgic
implant
option
unit
state
creat
organ
procur
transplant
network
optn
help
develop
system
would
guid
organ
alloc
uno
nonprofit
organ
ever
run
optn
manag
sinc
initi
contract
award
uno
help
develop
organshar
system
donor
heart
alloc
base
degre
ill
recipi
blood
type
compat
size
dispar
length
time
candid
activ
wait
transplant
algorithm
list
patient
evolv
year
two
tier
three
tier
system
modifi
broader
organ
share
current
heart
alloc
system
base
tier
medic
urgenc
statu
statu
statu
statu
given
highest
prioriti
wait
list
statu
repres
stabl
candid
gener
pulmonari
function
high
inhal
nitric
oxid
requir
typic
wean
slowli
prior
attempt
extub
prolong
intub
increas
risk
ventilatorassoci
pneumonia
especi
posttranspl
popul
significantli
immunosuppress
first
hour
follow
heart
transplant
critic
shortand
longterm
prognosi
patient
major
complic
discuss
later
vital
success
intens
care
team
abil
anticip
problem
reach
irrevers
point
respond
urgent
intervent
one
major
differ
heart
transplant
recipi
arriv
cicu
denerv
heart
cardiac
physiolog
denerv
heart
uniqu
deserv
special
attent
normal
cardiac
physiolog
involv
sympathet
parasympathet
innerv
autonom
nervou
system
heart
transplant
complet
transect
neural
axon
heart
result
loss
cardiac
norepinephrin
reserv
affer
denerv
impair
respons
chang
cardiac
fill
pressur
sympathet
parasympathet
regul
approach
postop
inotrop
support
heart
transplant
patient
vari
center
unfortun
data
guid
protocol
isoproterenol
use
uncommon
cicu
use
dose
newli
admit
postop
heart
transplant
patient
institut
argu
potenti
lusitrop
effect
isoproteronol
enhanc
diastol
relax
typic
heart
transplant
recipi
requir
degre
inotrop
support
dobutamin
per
minut
milrinon
per
minut
dopamin
per
minut
andor
epinephrin
commonli
use
receptor
denerv
heart
extrem
sensit
agonist
durat
inotrop
support
often
affect
donorrecipi
age
ischem
time
effect
cardioplegia
mani
transplant
program
implement
critic
care
protocol
inotrop
wean
typic
occur
day
uncompl
heart
transplant
critic
care
team
often
abl
rapidli
wean
sedat
assess
neurolog
statu
provid
patient
spontan
breath
trial
prior
extub
within
first
hour
postop
individu
sever
rv
dysfunct
volum
overload
margin
despit
optim
vasopressor
support
methylen
blue
use
treat
vs
follow
heart
transplant
methylen
blue
given
singl
infus
minut
typic
mg
kg
describ
leyh
et
al
follow
infus
methylen
blue
patient
may
develop
greenish
discolor
urin
occasion
skin
puls
oximetri
unreli
light
emiss
interfer
methylen
blue
mortal
seen
methylen
blue
use
individu
sever
renal
insuffici
defici
assess
compat
abo
blood
group
major
histocompat
antigen
prior
transplant
dramat
decreas
incid
hyperacut
reject
hyperacut
reject
occur
circul
preform
antibodi
donor
heart
present
result
graft
failur
within
minut
hour
transplant
immedi
mc
typic
requir
form
ecmo
plasmapheresi
aggress
immunosuppress
focus
elimin
remov
preform
antibodi
provid
best
chanc
surviv
individu
antithymocyt
globulin
atg
intraven
immunoglobulin
ivig
complement
inhibitor
eculizumab
use
treat
complic
patient
cardiogen
shock
ecmo
support
may
indic
antireject
therapi
administ
rv
failur
anoth
common
complic
immedi
postop
period
sever
factor
contribut
likelihood
rv
failur
younger
donor
heart
rv
elev
pa
pressur
therefor
suscept
acut
rv
failur
time
implant
recipi
pulmonari
hypertens
princip
demonstr
anim
model
guyton
et
al
sever
earli
posttranspl
death
attribut
acut
rv
failur
patient
known
pulmonari
hypertens
risk
death
acut
rv
failur
follow
heart
transplant
report
griepp
et
al
see
box
goal
treatment
acut
rv
failur
adapt
stobierskadzierzek
et
al
rv
failur
character
progress
congest
symptom
impair
rv
fill
andor
reduc
cardiac
output
increas
rv
afterload
preload
lead
ventricular
dilat
diminish
effer
denerv
result
elev
rest
heart
rate
decreas
inotrop
chronotrop
respons
exercis
normal
sinoatri
sa
node
activ
often
impair
heart
transplant
initi
mani
patient
suffer
rel
sinu
bradycardia
often
result
trauma
sa
node
follow
surgeri
prolong
ischem
time
amiodaron
use
recipi
prior
heart
transplant
often
treat
temporari
cardiac
pace
surgic
place
epicardi
pace
wire
terbutalin
use
mix
result
temporarili
increas
rest
heart
rate
follow
wean
inotrop
patient
abl
discontinu
terbutalin
within
first
month
transplant
less
patient
requir
pacemak
implant
sinu
tachycardia
commonli
encount
arrhythmia
consid
normal
physiolog
respons
denerv
postop
atrial
arrhythmia
includ
atrial
tachycardia
atrial
flutter
atrial
fibril
occur
rate
older
seri
surgic
techniqu
may
reduc
occurr
rate
bicav
approach
increasingli
replac
biatrial
anastomosi
arrhythmia
may
trigger
postop
inflamm
origin
sutur
line
highdos
inotrop
support
immedi
postop
period
denerv
heart
especi
sensit
av
nodal
block
agent
attempt
reduc
inotrop
initi
intervent
follow
cautiou
consider
calcium
channel
blocker
less
prefer
concern
lv
dysfunct
amiodaron
consid
digoxin
unlik
effect
cardiac
transplant
patient
given
primari
mechan
action
effect
vagal
tone
extrem
caution
must
appli
consid
adenosin
result
prolong
ventricular
asystol
adenosin
consid
heart
transplant
patient
recommend
mg
via
peripher
iv
mg
via
central
iv
addit
kept
mind
rate
control
agent
verapamil
diltiazem
amiodaron
significantli
increas
immunosuppress
drug
level
vasoplegia
syndrom
vs
rare
lethal
follow
heart
transplant
consist
sever
refractori
hypotens
metabol
acidosi
low
system
vascular
resist
vs
seen
follow
cardiac
surgeri
use
cardiopulmonari
bypass
uniqu
heart
transplant
risk
factor
includ
preoper
intraven
heparin
ace
inhibitor
calcium
channel
blocker
incid
vs
may
also
increas
individu
bridg
transplant
mc
pathophysiolog
thought
relat
upregul
sever
vasodilatori
mechan
includ
circul
endotheli
injuri
dysregul
nitric
oxid
synthesi
addit
associ
vasodilatori
shock
vasopressin
defici
describ
argenziano
et
al
treatment
approach
includ
hemodynam
support
vasopressor
norepinephrin
vasopressin
pure
agonist
phenylephrin
typic
abl
restor
mean
arteri
blood
pressur
refractori
hypotens
present
tabl
manag
pgd
predominantli
support
escal
appropri
inotrop
mechan
support
may
role
therapi
plasmapheresi
requir
futur
studi
intensivist
focu
prevent
pgd
occur
box
describ
sever
prevent
measur
decreas
incid
pgd
kidney
function
major
predictor
mortal
wait
list
mortal
transplant
studi
demonstr
everi
mgdl
increas
creatinin
increas
graft
failur
year
data
uno
registri
suggest
serum
creatinin
greater
associ
twice
mortal
risk
year
acut
kidney
injuri
aki
commonli
encount
cicu
follow
heart
transplant
patient
develop
clinic
signific
aki
follow
cardiac
surgeri
pathophysiolog
aki
follow
cardiac
surgeri
multifactori
includ
limit
cellular
ischemia
lead
tubular
vascular
endotheli
injuri
loss
autoregul
glomerular
filtrat
rate
tricuspid
valv
insuffici
patient
bridg
heart
transplant
mc
increas
risk
periop
rv
failur
technic
challeng
surgic
approach
increas
blood
product
requir
prolong
ischem
time
focal
cardiac
tamponad
acut
respiratori
distress
syndrom
ard
presenc
pulmonari
hypertens
caus
acut
rv
failur
fail
rv
often
result
worsen
venou
congest
subsequ
renal
hepat
intestin
dysfunct
treatment
rv
failur
includ
volum
optim
inotrop
support
afterload
reduct
mechan
circulatori
support
inhal
nitric
oxid
ino
commonli
use
postop
heart
transplant
patient
elev
pulmonari
pressur
rv
dysfunct
normal
dose
ino
ppm
typic
wean
prior
extub
ino
effect
short
term
limit
longerterm
use
therefor
modal
unload
right
ventricl
milrinon
isoproterenol
nesiritid
sildenafil
also
util
primari
graft
dysfunct
pgd
compar
secondari
graft
dysfunct
occur
discern
caus
hyperacut
reject
pulmonari
hypertens
lead
rv
failur
ishlt
held
consensu
confer
pgd
better
defin
clinic
condit
manag
pgd
involv
isol
rv
lv
manifest
biventricular
donat
noncardiac
organ
except
lung
donat
associ
decreas
incid
pgd
use
data
uno
altern
studi
show
high
degre
correl
heart
lung
pgd
patient
undergo
pair
transplant
singlecent
studi
show
incid
pgd
group
receiv
emerg
heart
transplant
wherea
incid
transplant
done
elect
mean
arteri
blood
pressur
less
mm
hg
initi
system
inflammatori
respons
hemolysisrel
kidney
injuri
due
gener
plasmafre
hemoglobin
iron
furthermor
anemia
red
blood
cell
rbc
transfus
need
surgic
reexplor
potenti
aki
preserv
kidney
function
mainten
adequ
urin
output
one
critic
job
cardiac
intensivist
set
escal
dosag
diuret
may
role
shortterm
nesiritid
promot
diuresi
maintain
urin
output
intensivist
must
avoid
nephrotox
medic
prevent
hypotens
episod
maintain
euvolemia
help
ensur
success
recoveri
kidney
function
follow
heart
transplant
preserv
kidney
function
allow
optim
immunosuppress
enhanc
graft
surviv
despit
best
effort
transplant
patient
may
requir
continu
renal
replac
therapi
crrt
even
intermitt
hemodialysi
ihd
patient
regain
renal
function
within
month
longterm
hemodialysi
significantli
decreas
qualiti
life
individu
egfr
less
prior
transplant
consid
dual
organ
heartkidney
transplant
adapt
immun
system
highli
modifi
special
effect
defens
system
target
appropri
adapt
immun
system
help
preserv
human
life
inappropri
target
lead
demis
individu
transplant
organ
amplif
immun
system
begin
moment
first
surgic
incis
tissu
factor
trigger
upregul
cytokin
increas
product
cellular
humor
compon
immun
system
immun
system
becom
prime
target
destroy
anyth
foreign
even
ident
donor
recipi
match
organ
carri
risk
reject
life
recipi
recipi
immun
system
constantli
survey
donor
heart
marker
antigen
would
identifi
foreign
strategi
adopt
transplant
center
earli
use
multipl
drug
sequenti
synergist
decreas
chanc
reject
attempt
reduc
overal
toxic
side
effect
medic
immunosuppress
may
divid
earli
mainten
immunosuppress
earli
immunosuppress
refer
therapeut
use
time
transplant
mainten
immunosuppress
often
start
within
hour
heart
transplant
continu
long
term
consider
overlap
earli
immunosuppress
regimen
treatment
establish
reject
episod
commonli
use
drug
list
tabl
earli
immunosuppress
highli
sensit
patient
elev
level
circul
antibodi
class
iclass
ii
human
leukocyt
antigen
may
begin
prior
heart
transplant
patient
often
refer
desensit
therapi
individu
highest
risk
develop
reject
certain
transplant
center
special
desensit
implement
protocol
focu
reduc
individu
level
sensit
current
desensit
strategi
includ
bortezomib
plasmapheresi
rituximab
ivig
new
studi
look
use
monoclon
antibodi
eculizumab
highli
sensit
individu
goal
decreas
likelihood
reject
ultim
improv
longterm
surviv
heart
transplant
patient
typic
receiv
highdos
steroid
time
transplant
follow
rel
slow
taper
approxim
transplant
program
util
induct
therapi
decis
use
induct
therapi
balanc
risk
increas
infect
benefit
potenti
decreas
reject
individu
higher
risk
reject
typic
undergo
induct
therapi
commonli
atg
transplant
recipi
typic
receiv
standard
tripl
therapi
immedi
follow
surgeri
standard
tripl
drug
therapi
consist
calcineurin
inhibitor
cni
commonli
tacrolimu
less
use
cyclosporin
antiprolif
mycophenol
mofetil
mycophenol
acid
azathioprin
steroid
mani
transplant
program
renalspar
protocol
patient
underli
renal
dysfunct
induct
therapi
atg
allow
clinician
safe
withhold
calcineurin
inhibitor
first
day
effort
avoid
nephrotox
immunosuppress
regimen
transit
earli
mainten
therapi
immunosuppress
medic
wean
target
lower
therapeut
drug
level
reduc
risk
associ
morbid
approxim
patient
wean
corticosteroid
year
first
year
mainten
immunosuppress
driven
part
biopsi
result
echocardiograph
find
patient
toler
medic
typic
mainten
therapi
includ
tacrolimu
mycophenol
lowdos
prednison
individu
switch
prolifer
signal
inhibitor
psi
sirolimu
everolimu
instead
antiprolif
agent
adequ
wound
heal
occur
multipl
indic
switch
psi
discuss
later
psi
use
discourag
first
month
given
associ
poor
wound
heal
signific
nephrotox
newer
laboratori
test
tcell
immun
function
assay
may
hold
promis
allow
clinician
target
lowest
effect
dose
immunosuppress
medic
strategi
promis
reduc
complic
side
effect
associ
higher
dosag
medic
patient
stabil
outpati
mainten
regimen
incid
reject
drop
dramat
year
patient
present
lv
dysfunct
neg
workup
reject
diagnosi
cardiac
allograft
vasculopathi
cav
must
consid
cav
uniqu
process
pathophysiolog
differ
tradit
atherosclerosi
cav
occur
along
spectrum
continu
lead
caus
longterm
mortal
beyond
first
postop
year
develop
cav
within
first
month
confer
much
higher
mortal
compar
individu
evid
cav
earli
cav
typic
diffus
process
affect
distal
vessel
coronari
vascular
bed
littl
hope
success
intervent
late
develop
cav
much
like
involv
proxim
vessel
focal
natur
pathophysiolog
suggest
acut
chronic
reject
play
signific
role
develop
cav
mani
program
variou
prophylact
regimen
cav
guidelin
provid
class
recommend
statin
therapi
strict
control
cardiovascular
risk
factor
treatment
cav
percutan
intervent
rare
situat
coronari
bypass
surgeri
larg
depend
lesion
locat
length
treatment
beyond
revascular
includ
optim
immunosuppress
use
psi
sirolimu
everolimu
decreas
progress
cav
cav
clear
indic
switch
patient
antimetabolit
psi
patient
progress
cav
may
develop
sever
graft
dysfunct
retransplant
therapeut
option
infect
common
complic
follow
heart
transplant
recogn
durat
time
transplant
degre
posttranspl
immunosuppress
presenc
intravascular
devic
assist
gener
differenti
diagnosi
although
transplant
recipi
increas
risk
unusu
infect
microbiolog
gener
dictat
time
transplant
fig
gener
infect
trigger
acut
decompens
caus
septic
shock
usual
bacteri
natur
possibl
except
influenza
although
bacteremia
common
mortal
popul
higher
nontranspl
popul
like
due
increas
vigil
result
earlier
identif
blunt
host
inflammatori
respons
recent
health
care
contact
antibiot
exposur
influenc
likelihood
resist
gramposit
organ
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococcu
vre
resist
gram
neg
pseudomona
acinetobact
vre
infrequ
caus
sever
ill
broad
spectrum
antibiot
therapi
vancomycin
agent
antipseudomon
activ
consid
firstlin
treatment
local
microbiolog
high
percentag
extendedspectrum
esbl
produc
consider
given
carbapenem
presenc
indwel
central
venou
cathet
endovascular
devic
warrant
mrsa
coverag
vancomycin
addit
presenc
devic
may
communityacquir
pathogen
patient
present
short
breath
cough
infiltr
chest
radiograph
month
like
develop
communityacquir
pneumonia
wherea
month
opportunist
infect
much
common
subacut
present
type
degre
immunosuppress
use
recent
increas
immunosuppress
time
transplant
must
use
assess
risk
unusu
pathogen
care
must
also
taken
consid
noninfecti
etiolog
patient
multipl
reason
sepsislik
syndrom
lateonset
atrial
arrhythmia
repres
underli
episod
reject
syncop
palpit
taken
serious
patient
popul
sever
case
reject
justifi
empir
antifung
treatment
echinocandin
extens
histori
antibiot
exposur
intraabdomin
surgeri
total
parenter
nutrit
use
dramat
increas
incid
candidemia
earli
posttranspl
period
highest
risk
period
develop
opportunist
infect
immunosuppress
regimen
intens
first
month
transplant
use
prophylaxi
significantli
reduc
burden
opportunist
infect
common
prophylact
regimen
includ
valganciclovir
cytomegaloviru
cmv
trimethoprimsulfamethoxazol
pneumocysti
jiroveci
pcp
fluconazol
coccidioidomycosi
nystatin
swish
swallow
oral
candidiasi
fungal
infect
peak
month
transplant
commonli
occur
individu
recent
treat
broad
spectrum
antibiot
month
infect
larg
relat
common
tabl
review
current
treatment
recommend
acut
cellular
antibodymedi
reject
major
limit
field
transplant
relat
sequela
chronic
immunosuppress
immunosuppress
drug
decreas
risk
reject
treat
establish
reject
price
start
year
follow
transplant
incid
malign
begin
increas
year
becom
lead
caus
death
studi
demonstr
increas
incid
malign
heart
transplant
patient
compar
kidney
transplant
recipi
like
repres
differ
degre
immunosuppress
requir
prevent
reject
heart
kidney
current
strategi
includ
transit
cni
antimetabolit
use
psi
demonstr
reduc
incid
progress
malign
addit
side
effect
immunosuppress
import
cardiac
intensivist
awar
drugdrug
interact
occur
patient
chronic
immunosuppress
box
demonstr
immunosuppress
level
affect
variou
drug
research
address
suppli
demand
mismatch
donor
potenti
recipi
gener
excit
discoveri
organ
preserv
techniqu
may
result
increas
donor
pool
new
pharmacotherapeut
hold
promis
may
manifest
bradyarrhythmia
potenti
progress
cardiac
arrest
andor
asystol
conduct
abnorm
may
present
case
cav
andor
signific
cardiac
fibrosi
ventricular
arrhythmia
rare
encount
heart
transplant
develop
omin
newonset
ventricular
arrhythmia
may
first
represent
cav
acut
reject
everi
heart
transplant
patient
present
new
arrhythmia
undergo
thorough
evalu
major
heart
transplant
recipi
demonstr
normal
lv
rv
function
time
discharg
decreas
cardiac
function
whether
accompani
symptom
must
taken
serious
thoroughli
evalu
two
major
caus
decreas
cardiac
function
transplant
cardiac
allograft
reject
cardiac
allograft
vasculopathi
patient
suffer
acut
reject
present
wide
varieti
symptom
clinic
find
reject
suspect
aggress
treatment
initi
soon
possibl
patient
quickli
decompens
gold
standard
diagnos
reject
endomyocardi
biopsi
sensit
limit
result
may
confirm
hour
wait
tissu
diagnosi
patient
popul
treat
discourag
patient
may
die
potenti
treatabl
reject
episod
three
major
type
reject
hyperacut
reject
discuss
earlier
acut
cellular
reject
acr
antibodymedi
reject
amr
revis
grade
system
adopt
ishlt
effort
standard
definit
grade
system
base
histolog
grade
includ
endotheli
activ
intravascular
macrophag
immunopatholog
deposit
complement
human
leukocyt
antigen
amr
tabl
sever
factor
must
consid
suspicion
acut
reject
grade
scheme
stratifi
biopsi
base
histolog
immunolog
evid
antibodymedi
reject
neg
either
histolog
immunolog
evid
antibodymedi
reject
suspici
parmi
respect
histolog
immunolog
evid
antibodymedi
reject
posit
final
categori
sever
find
myocardi
destruct
decreas
episod
reject
without
increas
risk
infect
identif
biomark
allow
earlier
detect
reject
activ
develop
improv
techniqu
optim
donorrecipi
immunolog
match
help
reduc
risk
reject
show
signific
promis
technolog
advanc
allow
improv
mechan
support
option
decreas
wait
list
mortal
ahf
patient
field
await
excit
futur
discoveri
focu
improv
candid
select
meticul
preand
posttranspl
manag
improv
outcom
qualiti
life
ahf
patient
